06.30.2009 - Oragenics, Inc. Announces $5,000,000 in New Financing, and Changes its Board of Directors and Management
(Alachua, FL) – (June 30, 2009) – The Florida based biotechnology firm Oragenics, Inc., announces that it has closed an investment contract with the Koski Family Limited Partnership to provide new capital for continuing operations. - read more
05.07.2009 - Oragenics, Inc. Continues to Explore Strategic Alternatives to Fund Continuing Operations
(Alachua, FL) – (May 7, 2009) – The Florida-based biotechnology firm Oragenics announces that it continues to seek strategic alternatives to fund its continuing operations. These alternatives include, but are not limited to, raising capital through the sale of equity, the sale of specific business units, and the sale of the entire Company. If our efforts are unsuccessful, we may be forced to discontinue operations and liquidate the Company’s assets. - read more
|
EvoraPlus is a one-of-a-kind probiotic mint that naturally supports gum and tooth health while freshening breath and whitening teeth.
|
|
|
ORAGENICS, INC.
Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies and a primary focus on commercialization. The corporate strategy is to bring products to market as quickly as possible and use the proceeds to further the development and commercialization of the remaining technologies. In addition to marketed products based on the ProBiora3 technology, the Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health. Oragenics has developed platform technologies with respect to its products, thereby creating a potential pipeline of future products, which the Company expects to develop.
|
 |
|
|
|
